Substack · Phaetrix Investing · Phaetrix
Eli Lilly Reassessed: Earned Part of the Rally, Still a Hold
The business delivered more than I expected. Now Lilly has to prove its metabolic platform can justify a trillion-dollar valuation.
Desde publicación +3,1 % α +3,3 p. p. vs S&P 500 · USD